WP
CRBP icon

Woodline Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Woodline Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-249,259
Closed -$11.3M – 622
2024
Q2 		$11.3M Buy
249,259
+208,278
+508% +$8.76M 0.11% 233
2024
Q1 		$1.61M Buy
+40,981
New +$1.01M 0.01% 439

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Woodline Partners's CRBP Position: Q3 2024 in Review

Woodline Partners sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 249,259 shares — an estimated $11.3M sold.

Woodline Partners first reported a position in CRBP in Q1 2024 and held it in 2 quarters. The position peaked at $11.3M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Woodline Partners reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Woodline Partners sold 249,259 Corbus Pharmaceuticals shares in Q3 2024, an estimated $11.3M.
  • Woodline Partners first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Woodline Partners's Corbus Pharmaceuticals position peaked at $11.3M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.